FDA Expands Vutrisiran Use for Transthyretin Amyloidosis Cardiomyopathy
- A treatment administered every three months reduces the risk of cardiovascular death.
- Food and Drug Governance (FDA) has expanded the authorization for Vutrisiran to include the treatment of amyloid cardiomyopathy mediated by transthyretin (ATTR-CM), including its hereditary form.
- ATTR-CM is a progressive and possibly fatal condition affecting an estimated 150,000 people in the U.S.
A treatment administered every three months reduces the risk of cardiovascular death.
The U.S. Food and Drug Governance (FDA) has expanded the authorization for Vutrisiran to include the treatment of amyloid cardiomyopathy mediated by transthyretin (ATTR-CM), including its hereditary form. The drug aims to decrease the risk of cardiovascular death, hospitalizations, and urgent care visits for heart failure.
A Disease affecting Thousands
Table of Contents
ATTR-CM is a progressive and possibly fatal condition affecting an estimated 150,000 people in the U.S. The disease stems from the accumulation of transthyretin (TTR) fibers in heart tissues, leading to irreversible cardiovascular damage and premature death.
Vutrisiran, administered via subcutaneous injection every three months, uses RNA interference to rapidly reduce TTR production. This limits the formation of amyloid fibrils and slows disease progression, according to medscape.
Helios-B Study Shows Promise
The FDA’s approval is based on Phase 3 clinical trial results from the Helios-B study. The study indicated that Vutrisiran substantially reduced the death rate from any cause and recurrent cardiovascular events in patients with ATTR-CM. the study achieved statistical importance across all 10 predefined primary and secondary objectives, compared to a placebo.
The findings were presented at the Congress of the European Cardiology Society and published in *The New England Journal of Medicine*.
Understanding ATTR-CM
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive condition caused by the buildup of abnormal transthyretin fibrils (TTR) in the heart muscle. These deposits compromise the heart’s structure and function, potentially leading to heart failure and other severe complications.
Causes of ATTR-CM
Transthyretin amyloidosis occurs when the TTR protein, normally produced by the liver, becomes unstable and forms amyloid deposits in various tissues, including the heart. There are two primary forms of the disease:
Wild-type (ATTRwt): This form appears spontaneously, most often in men older than 60.
Hereditary (ATTRv): This form is caused by inherited genetic mutations that led to abnormal TTR production.
symptoms of ATTR-CM
The disease typically progresses slowly, and initial symptoms can be nonspecific, making diagnosis challenging. Common symptoms include:
Cardiovascular: Heart failure with preserved ejection fraction (HFpEF),arrhythmias,syncope.
Neurological: Bilateral carpal tunnel syndrome, peripheral neuropathy.
General: Chronic fatigue, unexplained weight loss.
Diagnosis and Treatment
Diagnosing ATTR-CM involves tests such as echocardiography, bone scintigraphy with bisphosphonates, genetic testing, and potentially a cardiac biopsy.
Treatment focuses on slowing disease progression and improving quality of life. Available therapies include:
TTR Stabilizers: These prevent the formation of amyloid fibers.
RNA Interference: This reduces TTR production.
Liver or Heart Transplant: These are considered in severe cases.
ATTR-CM is a serious condition requiring early diagnosis and appropriate treatment to prevent irreversible heart damage. Advances in TTR-reducing therapies offer hope for patients, potentially prolonging survival and enhancing quality of life.
ATTR-CM: Your Questions Answered
What is ATTR-CM?
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and potentially fatal condition. It is a rare form of amyloidosis that affects the heart. The disease stems from the accumulation of transthyretin (TTR) protein fibers in heart tissues, leading to irreversible cardiovascular damage and premature death. It affects an estimated 150,000 people in the U.S.
What Causes ATTR-CM?
ATTR-CM is caused by the buildup of abnormal transthyretin (TTR) protein fibrils in the heart muscle. These deposits compromise the heart’s structure and function, potentially leading to heart failure and other severe complications. There are two primary forms:
Wild-type (ATTRwt): this form appears spontaneously, most often in men older than 60.
Hereditary (ATTRv): This form is caused by inherited genetic mutations that lead to abnormal TTR production.
What are the Symptoms of ATTR-CM?
Symptoms of ATTR-CM can be nonspecific, making diagnosis challenging. Common symptoms include:
Cardiovascular: Heart failure with preserved ejection fraction (HFpEF), arrhythmias, syncope.
Neurological: Bilateral carpal tunnel syndrome,peripheral neuropathy.
General: chronic fatigue, unexplained weight loss.
How is ATTR-CM Diagnosed?
diagnosing ATTR-CM involves tests such as:
Echocardiography
Bone scintigraphy with bisphosphonates
Genetic testing
Potentially a cardiac biopsy
What are the Current Treatment Options for ATTR-CM?
Treatment focuses on slowing disease progression and improving quality of life. Available therapies include:
TTR Stabilizers: These prevent the formation of amyloid fibers.
RNA Interference: This reduces TTR production.
Liver or Heart Transplant: Considered in severe cases.
Is There Any Promising New Treatment for ATTR-CM?
Yes, Vutrisiran, administered via subcutaneous injection every three months, uses RNA interference to rapidly reduce TTR production. This limits the formation of amyloid fibrils and slows disease progression. The U.S. Food and Drug Governance (FDA) has expanded the authorization for Vutrisiran to include the treatment of amyloid cardiomyopathy mediated by transthyretin (ATTR-CM), including its hereditary form. The drug aims to decrease the risk of cardiovascular death, hospitalizations, and urgent care visits for heart failure.
What is the Impact of Vutrisiran Treatment?
The FDA’s approval is based on Phase 3 clinical trial results from the Helios-B study. The study indicated that Vutrisiran substantially reduced the death rate from any cause and recurrent cardiovascular events in patients with ATTR-CM. The findings were presented at the Congress of the European Cardiology Society and published in The New England Journal of Medicine.
Key differences Between ATTRwt and ATTRv
| Feature | ATTRwt | ATTRv |
| —————- | —————————— | ———————————– |
| Cause | Spontaneous | Inherited genetic mutation |
| Typical Onset | Men older than 60 | Varies depending on the mutation |
| Common Symptoms | Similar to ATTRv | Similar to ATTRwt |
| Disease Progression | Progressive, with a slow onset | Progressive with a slow to rapid onset |